GlassScriptPhysician profile
William T Garrett
NPI 1750351862
$4,996.96
in general payments reported to CMS, 2019-2025
42 companies · $14.60 in 2025
The $14.60 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,756 · 2020: $1,005 · 2021: $1,026 · 2022: $814 · 2023: $306 · 2024: $75.30 · 2025: $14.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $395.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $480.47 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $480.09 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $385.29 | 2019-2024 | Ultomiris, Soliris |
| Biogen, INC. | $305.34 | 2019-2022 | |
| Amgen INC. | $258.25 | 2019-2022 | |
| Ucb, INC. | $253.98 | 2019-2023 | Briviact |
| Novartis Pharmaceuticals Corporation | $248.82 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $236.75 | 2019-2021 | |
| Abbvie INC. | $235.58 | 2021-2023 | |
| Sk Life Science, INC. | $234.59 | 2020-2023 | |
| Genzyme Corporation | $188.44 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $164.57 | 2021-2022 | |
| Eisai INC. | $146.39 | 2019-2025 | |
| Mdd US Operations, LLC | $139.89 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $119.86 | 2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Garrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.